Core Insights - Cormorant Asset Management sold its entire stake in Arcellx for an estimated $63.63 million, liquidating 775,000 shares as of February 17, 2026 [1][2] Company Overview - Arcellx's current stock price is $114.51, with a market capitalization of $6.7 billion and a revenue of $22.3 million over the trailing twelve months (TTM). The company reported a net income loss of $228.9 million TTM [4] - Arcellx is focused on developing proprietary ddCAR and ARC-T cell platforms to address unmet medical needs in relapsed or refractory cancers, with a pipeline that includes candidates for hematologic malignancies and solid tumors [5][8] Recent Developments - Arcellx shares have increased by 80% this year, driven by the development of next-generation CAR-T cell therapies, particularly anitocabtagene autoleucel, which has shown strong clinical responses [9] - A recent takeover agreement from Gilead Sciences values Arcellx at approximately $7.8 billion, offering shareholders $115 per share in cash, along with potential additional payments tied to future sales milestones [10] Investment Implications - Following the sale, Cormorant's position in Arcellx dropped from 4.4% of its 13F reportable assets under management (AUM) to zero. The fund's top holdings now include NASDAQ:PRAX at $280 million (15.9% of AUM) and NASDAQ:BBOT at $223.84 million (12.7% of AUM) [7] - Arcellx's stock performance has significantly outpaced the S&P 500, which gained approximately 19% over the same period [7]

FDA Approvals & Rejections - Armata Pharmaceuticals received FDA QIDP designation for AP-SA02, a bacteriophage-based candidate for complicated Staphylococcus aureus bacteremia, providing five years of market exclusivity and eligibility for Fast Track status [2][3] - Allurion Technologies gained FDA PMA approval for the Gastric Balloon System, a swallowable Smart Capsule that promotes fullness for about four months, targeting patients with a BMI of 30-40 [4][5] - Eton Pharmaceuticals' DESMODA oral solution was approved for managing central diabetes insipidus, with an expected peak annual sales of $30 million - $50 million [9][11] Deals - Gilead Sciences announced the acquisition of Arcellx for $115 per share, totaling an implied equity value of $7.8 billion, enhancing its position in cell therapy [12][13] - Vir Biotechnology entered a global collaboration with Astellas for VIR-5500, receiving $335 million in upfront payments and potential additional milestones of up to $1.37 billion [14][15][16] - Kairos Pharma signed a term sheet to acquire two oncology assets from Celyn Therapeutics, focusing on cancer therapeutics [17][18][20] Clinical Trials - Breakthroughs - MoonLake Immunotherapeutics reported positive Phase 2 trial results for Sonelokimab in axial spondyloarthritis, with 81% of patients achieving an ASAS40 response at Week 12 [21][22] - Novo Nordisk's CagriSema missed its primary endpoint in a Phase 3 trial against Zepbound, showing 23% weight loss compared to 25.5% with Tirzepatide [25][26][27] - Gossamer Bio's seralutinib missed the primary endpoint in the PROSERA Phase 3 study for pulmonary arterial hypertension, showing a placebo-adjusted improvement in Six-Minute Walk Distance [28][30][31] - Argenx's VYVGART met primary goals in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis, demonstrating significant improvement in ocular scores [37][38][39]